CancerPathology

Mammaglobin-A expression is highly specific for tumors derived from the breast, the female genital tract and salivary gland tumors

Presented in 13th Emirates Pathology, Digital Pathology & Cancer Conference Holiday Inn Dubai, UAE & Virtual
Poster Presenter Name: Dr. Natalia Gorbokon (Germany)
Global Journal of Pathology & Laboratory Medicine

Unified Citation Journals, Pathology 2023, ISSN2754-0952
Biography:
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Natalia Gorbokon1, Patrick Timm1, Anne Menz1, Franziska Büscheck1, Maximilian Lennartz1, Andreas M Luebke1, Christian Bernreuther1, Patrick Lebok1, Till S Clauditz1, Frank Jacobsen1, Guido Sauter1, Ria Uhlig1, Stefan Steurer1, Sarah Minner1, Andreas H Marx1,2, Ronald Simon1, Eike Burandt1, Till Krech1,3

1 Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 Department of Pathology, Academic Hospital Fuerth, Fuerth Germany
3 Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany

Abstract:
Human mammaglobin-A (SCGB2A2) is a small epithelial secretory protein with unknown function. Because of its frequent expression in breast epithelial cells, it is used as a diagnostic marker for breast cancer and represents an attractive target for novel therapies involving adaptive T cell transfer and antitumor vaccines for breast cancer patients. However, there is growing evidence that mammaglobin-A expression is not limited to breast cancers. In order to comprehensively determine mammaglobin-A expression in normal and neoplastic tissues, a tissue microarray containing 16,328 samples from 128 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Mammaglobin-A positivity was found in 37 of 128 tumor categories, 32 of which were derived of one of four organs: breast (6 tumor categories), endometrium (5 tumor categories), ovary (5 tumor categories), and salivary glands (16 tumor categories). Only 5 additional tumor types showed occasional mammaglobin positivity.
These tumors mostly exhibited a weak mammaglobin-A staining and included medullary thyroid cancer, teratoma of the testis, squamous cell carcinoma of skin and the pharynx, and prostatic adenocarcinoma (Gleason 5+5=10). Among 1,139 evaluable invasive breast carcinomas of no special type (NST), low mammaglobin-A immunostaining was linked to high BRE grade (p=0.0011), a loss of estrogen and progesterone receptor expression (p<0.0001 each), and triple negative status (p<0.0001) but not to patient survival. In endometrial cancer, low mammaglobin-A immunostaining was linked to advanced tumor stage (p=0.0198). Although a similar trend was seen for endometrioid and serous high-grade carcinomas of the ovary, these associations did not reach statistical significance. In conclusion, our data characterize mammaglobin-A as a highly specific marker for tumors derived from either female organs or the salivary gland.
The potential use of anti-Mammaglobin therapies should be studied also in other mammaglobin-positive tumor types.

Keywords: Human mammaglobin-A (SCGB2A2), diagnostic marker, tissue microarray, immunohistochemistry

Tags:
Cancer, Immunodeficiency States, Immunophenotyping, Molecular Diagnostics & Proteomics, Evolutionary Medicine, Functional Identification & Biomarkers, Hematopoietic & other Malignancies, Anatomical Pathology, Clinical Pathology, Dermato Pathology, Forensic Pathology, Hemato Pathology, Histopathology, Molecular Pathology, Surgical Pathology, Histopathology, Chemical Pathology, Hematopathology, Histopathology, Cytopathology, Forensic Pathology, Dermatopathology, Clinical Biochemistry, Infection Control, Cytokines, Enzymology, Endocrinology, Cellular Lineage, Virology, Rheology, Toxicology, Neuropathology, Diagnostic Pathology, Mesothelial Proliferations, Transfusion medicine, Clinical microbiology, Cytogenetics, Molecular Genetics Pathology, Immunopathology, Veterinary Pathology, Anatomical Pathology, General Pathology

Upcoming Conferences;

  1. 14th Emirates Pathology, Digital Pathology & Cancer Conference 
    More Details: https://pathology.universeconferences.com/
    Submit your abstract/research papers/case- study here: https://pathology.universeconferences.com/submit-abstract/
    Attend as a Speaker/Poster/Delegate In-person kindly register here: https://pathology.universeconferences.com/registration/ 
    Attend as a Speaker/Poster/Delegate virtually kindly register here: https://pathology.universeconferences.com/virtual-registration/
  2. 12th World Digital Pathology & AI UCGCongress
    More Details: https://digitalpathology.ucgconferences.com/  
    Submit your abstract/research papers/case- study here: https://digitalpathology.ucgconferences.com/submit-abstract/
    Attend as a Speaker/Poster/Delegate In-person kindly register here: https://digitalpathology.ucgconferences.com/registration/
    Attend as a Speaker/Poster/Delegate virtually kindly register here: https://digitalpathology.ucgconferences.com/online-registration/

Related Articles

Back to top button